🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Race Oncology CEO speaks with Proactive Australia about the activation of the first Australian site for RC220 Phase 1 clinical trial in solid tumours. The study is now open to patient enrolment. Full interview: youtube.com/watch?v=ruKXiD… $RAC #biotech #clinicaltrial

The Race Oncology team are on the ground at this year's AACR Annual Meeting 2025 in Chicago! We are excited to make connections and share our work with our #anticancer and #cardioprotective drug #bisantrene.  #cardiooncology #oncology #cancerresearch #AACR2025 $RAC

Race Oncology has safely and successfully completed first patient dosing for the Phase 1 clinical trial in advanced solid tumours, at the study’s lead trial site Southside Cancer Care in Miranda, NSW. More: announcements.raceoncology.com/announcements/… $RAC #clinicaltrial #cardioprotection #oncology

Race Oncology CEO speaks with Proactive Australia about the company’s recent milestone as the first patient in its Phase 1 clinical trial has been safely and successfully dosed. More: youtu.be/uGz7fdjz2iw $RAC #cardioprotection #clinicaltrial #drugdevelopment

Race Oncology welcomes internationally renowned pharma execs Dr Jose Iglesias as CMO and Dr Simon Fisher as VP of Clinical, as we continue building momentum with our RC220 clinical programs and commercial strategy. More here: shorturl.at/hn9qB $RAC #GlobalExpertise

This #HeartWeek, we highlight the critical link between #cancer care & heart health ❤️🩺 Race Oncology researches #bisantrene to improve patient outcomes, by cardiovascular protection. Support your heart: Heart Foundation tips ➡️ heartfoundation.org.au/heart-week

Race Oncology Exec Chair Dr Pete Smith will be attending the 2025 ASCO Annual Meeting - the leading global #oncology conference - in Chicago next week! For a meeting at the event, contact [email protected] #ASCO25

Race Oncology is pleased to announce its attendance at the Gold Coast Investment Showcase by Vertical Events on 25-26 June, and an in-person investor briefing session in Brisbane on 27 June. More details on the events and how to register: announcements.raceoncology.com/announcements/… $RAC #GCIS

Not long to go! Don't miss Race Oncology at the Gold Coast Investment Showcase by Vertical Events on 25-26 June, and an in-person investor briefing session in Brisbane on 27 June. More details on the events and how to register: announcements.raceoncology.com/announcements/… $RAC #GCIS

We’ve wrapped up our presentation at the Gold Coast Investment Showcase!💡 $RAC CEO Dr Daniel Tillett shared the latest on our RC220 #cardioprotection + #anticancer clinical trial. Don't miss our investor briefing in Bris tomorrow. RSVP to [email protected]

Meet Dr Simon Fisher, VP of Medical Race Oncology. Watch this video to hear how Simon is bringing his vision and expertise to $RAC to progress RC220’s clinical development, and put patients at the heart of cancer care: youtu.be/mTNbZebtVW4

Missed Race Oncology at the Gold Coast Investment Showcase last week? 📈 You can watch a video of our CEO Dr. Daniel Tillett's presentation here: youtube.com/watch?v=d5IXke… #ASXbiotech #biotechinvestment #GCIS $RAC

Snapshots from last week's Race Oncology investor briefing in Brisbane! 📸 Check out this video for a glimpse of the event, including snaps of the venue & Executive Chairman Dr Pete Smith & CEO Dr Daniel Tillett presenting updates on Race Oncology's progress Thanks for joining!

Race Oncology is pleased to announce Human Research Ethics Committee approvals have been received from the Institutional Review Board of The University of Hong Kong to commence its Phase 1 clinical trial of RC220 in combination with #doxorubicin (RAC-010) Read more ➡️ shorturl.at/xM5eD

Join Race Oncology in Hobart on 6 Aug for an investor briefing with Dr Pete Smith & Dr Daniel Tillett! Will include an update on RC220 clinical program, a Q&A session and light lunch. Must RSVP by 28 July to [email protected] 🔗 shorturl.at/wGPR9

🚨 A transformative quarter for Race Oncology! CEO Dr Daniel Tillett spoke with Proactive Australia on: ✅First patient dosed with RC220 & RC220 in combo with doxorubicin ✅Key leadership changes that have strengthened $RAC's clinical team ✅Strong cash runway tinyurl.com/99duch99